Mason Carrico
Stock Analyst at Stephens & Co.
(3.69)
# 751
Out of 5,131 analysts
77
Total ratings
49.25%
Success rate
9.16%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $197 → $235 | $206.23 | +13.95% | 6 | Nov 13, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $1.8 → $2 | $1.71 | +16.96% | 6 | Nov 10, 2025 | |
| HOLX Hologic | Downgrades: Equal-Weight | $78 → $76 | $75.06 | +1.26% | 6 | Oct 22, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $6.5 → $11 | $11.39 | -3.42% | 2 | Sep 2, 2025 | |
| VCEL Vericel | Reiterates: Overweight | $67 | $35.96 | +86.32% | 3 | Jun 16, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $116.81 | -10.11% | 8 | May 20, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $18.12 | -22.74% | 6 | May 15, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.63 | +103.77% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $109.47 | +5.05% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $35.80 | +25.70% | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $55 | $104.85 | -47.54% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $4.24 | +41.51% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $16.10 | +5.59% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $74.60 | -30.29% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $4.49 | +345.43% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $33.18 | +23.57% | 7 | Jan 2, 2025 |
Natera
Nov 13, 2025
Maintains: Overweight
Price Target: $197 → $235
Current: $206.23
Upside: +13.95%
Pacific Biosciences of California
Nov 10, 2025
Maintains: Overweight
Price Target: $1.8 → $2
Current: $1.71
Upside: +16.96%
Hologic
Oct 22, 2025
Downgrades: Equal-Weight
Price Target: $78 → $76
Current: $75.06
Upside: +1.26%
NeoGenomics
Sep 2, 2025
Maintains: Overweight
Price Target: $6.5 → $11
Current: $11.39
Upside: -3.42%
Vericel
Jun 16, 2025
Reiterates: Overweight
Price Target: $67
Current: $35.96
Upside: +86.32%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $116.81
Upside: -10.11%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $18.12
Upside: -22.74%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.63
Upside: +103.77%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $109.47
Upside: +5.05%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $35.80
Upside: +25.70%
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $104.85
Upside: -47.54%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $4.24
Upside: +41.51%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $16.10
Upside: +5.59%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $74.60
Upside: -30.29%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $4.49
Upside: +345.43%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $33.18
Upside: +23.57%